Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interleukin‑1 blockade (anakinra) in acute severe ulcerative colitis
2017-001389-10Phase 2Unknown
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Anakinra + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Incidence of medical or surgical rescue therapy within 10 days. Status: unknown.
02
Drugs
anakinra
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-001389-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001389-10.